Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 6,370.00
-130.00 (-2.00%)
Last updated: Sep 1, 2026, 2:31 PM KST
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 78.13 billion as of September 1, 2026. Its market cap has decreased by -52.55% in one year.
Market Cap
78.13B
Enterprise Value
182.38B
Revenue
16.21B
Ranking
n/a
PE Ratio
n/a
Stock Price
6,370.00
ChartMarket Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 78.13B, a decrease of -78.33%. That is a compound annual growth rate of -25.21%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 1, 2026 | 78.13B | -49.42% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Helixmith | 142.75B |
| GC Genome | 140.01B |
| Genexine | 120.29B |
| MedPacto | 95.46B |
| Vaxcell-Bio Therapeutics | 93.15B |
| iNtRON Biotechnology | 86.50B |
| Amicogen | 67.49B |
| ENCell | 65.29B |